
Gilead Sciences Acquires Arcellx for $7.8 Billion to Advance Cancer Immunotherapies
Gilead Sciences Seals $7.8 Billion Deal for Arcellx to Boost CAR T-Cell Therapy In the rapidly evolving landscape of cancer immunotherapies, where breakthroughs are crucial for patient outcomes, Gilead Sciences, Inc. has made a significant move. The biopharmaceutical giant has announced a…












